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Combinations of cyclosporine (CSP) with methotrexate (MTX) have been widely used for immunosuppression
after allogeneic transplantation for acquired aplastic anemia. We compared outcomes with tacrolimus
(TAC)þMTX versus CSPþMTX after transplantation from HLA-identical siblings (SIB) or unrelated donors
(URD) in a retrospective cohort of 949 patients with severe aplastic anemia. Study endpoints included
hematopoietic recovery, graft failure, acute graft-versus-host disease (GVHD), chronic GVHD, and mortality.
TACþMTX was used more frequently in older patients and, in recent years, in both SIB and URD groups. In
multivariate analysis, TACþMTX was associated with a lower risk of mortality in URD recipients and with
slightly earlier absolute neutrophil count recovery in SIB recipients. Other outcomes did not differ statisticallyedgments on page 1781.
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Tacrolimusbetween the 2 regimens. No ﬁrm conclusions were reached regarding the relative merits of TACþMTX versus
CSPþMTX after hematopoietic cell transplantation for acquired aplastic anemia. Prospective studies would
be needed to determine whether the use of TACþMTX is associated with lower risk of mortality in URD
recipients with acquired aplastic anemia.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION violating the proportional hazards assumption were adjusted through
Allogeneic hematopoietic cell transplantation (HCT) is a
curative treatment for patients with severe aplastic anemia
(SAA), but graft failure and graft-versus-host disease (GVHD)
have impeded its success [1-8]. Combinations of cyclo-
sporine (CSP) or tacrolimus (TAC) with methotrexate (MTX)
have been widely used for immunosuppression after allo-
geneic HCT [2,9-13]. CSP has been used preferentially after
HCT for SAA [14] whereas TAC has been used preferentially
after HCT for hematological malignancies, since 3 prospec-
tive randomized studies of bone marrow transplantation
(BMT) showed lower risks of acute and chronic GVHD with
TAC more than a decade ago [9-11].
Outcomes with TACþMTX versus CSPþMTX after unre-
lated BMT for patients with SAA have been compared in only
1 Japanese study [15]. In a matched-pair retrospective study
of 94 patients, the risk of mortality was lower with the use of
TACþMTX [15], but rates of acute and chronic GVHD did not
differ statistically between the 2 prophylaxis regimens.
These results have not been validated in larger cohorts with
related or unrelated donors or evaluated in patients who
received growth factoremobilized peripheral blood cell
transplantation (PBSCT). The purpose of the current study
was to compare outcomes with TACþMTX versus CSPþMTX
after HCT for SAA using data collected by the Center for
International Bone Marrow Transplant Research (CIBMTR).
As observed in several studies mostly including patients with
hematological malignancies [9-12,16], we anticipated that
TACþMTX would be associated with lower risks of acute and
chronic GVHD after HCT for SAA.
METHODS
Patients
This retrospective study cohort included patients reported to the
CIBMTR who had their ﬁrst allogeneic BMT or PBSCT from HLA-identical
siblings (SIB) or from unrelated donors (URD) for treatment of acquired
SAA from January 2001 to December 2011. Patients who had GVHD pro-
phylaxis other than CSPþMTX or TACþMTX, those who received ex vivo T
celledepleted grafts, and those with congenital disorders were excluded,
leaving 949 eligible patients in the cohort. CIBMTR observational studies
using deidentiﬁed data comply with Health Insurance Portability and
Accountability Act regulations and are conducted with a waiver of informed
consent per the institutional review board of the Medical College of
Wisconsin.
Study Endpoints and Deﬁnitions
Study endpoints included hematopoietic recovery, secondary graft
failure, grades II to IV acute GVHD, grades III and IV acute GVHD, limited or
extensive chronic GVHD, and mortality. Time to neutrophil and platelet
recovery were deﬁned as the time from transplantation to the ﬁrst of 3
consecutive days with an absolute neutrophil count (ANC)  500/mm3 and
platelet count  20  109/L unsupported by transfusion for 7 days, respec-
tively. Secondary graft failure was deﬁned as subsequent loss of ANC
to < 500/mm3 and < 5% donor chimerism after neutrophil recovery. Acute
GVHD was graded according to consensus criteria [17]. Chronic GVHD was
diagnosed by historical criteria [18]. HLA matching was deﬁned as described
previously [19].
Statistical Analysis
Multivariate Cox regressionmodels were constructed to evaluate hazard
ratios (HR) for endpoints with TACþMTX compared with CSPþMTX. Factorsstratiﬁcation. A stepwise procedure was used in developing models for each
outcome, using a P value threshold of .05. All models were adjusted for graft
type (BMT versus PBSCT) and year of transplantation. Center effect was also
adjusted as a random effect to account for differences in practice at indi-
vidual centers, including the choice and targeted blood concentrations of
calcineurin inhibitors [20]. Analyses were performed separately in SIB and
URD recipients. Interactions between the main variable (GVHD prophylaxis)
and the adjusted covariates were tested at the signiﬁcance level of .01.
Proportions of causes of death were compared using Fisher’s exact test.
RESULTS
Transplantation from an HLA-identical Donor
Patient characteristics are summarized in Table 1. SIB
recipients who received TACþMTX were older and more
frequently of Caucasian race, had older donors, had more
frequent treatment for SAA with antithymocyte globulin
(ATG) before HCT, had HCT in more recent years with more
frequent use of cyclophosphamide-based conditioning, ATG
or alemtuzumab, and hematopoietic growth factors after
HCT. In multivariate analysis (Figure 1A), TACþMTX was
associated only with earlier ANC recovery (HR, 1.47; 95%
conﬁdence interval, 1.04 to 2.08; P¼ .03). Other outcomes did
not differ statistically between the 2 regimens. No statisti-
cally signiﬁcant interactions were observed between the
main variable and the adjusted covariates. The proportion of
graft failure as a cause of death was higher with TACþMTX
than with CSPþMTX (overall P ¼ .007; Table 2).
Transplantation from an URD
URD recipients who received TACþMTX were older
and less frequently of Caucasian race, had younger donors,
had HCT in more recent years with more frequent use of
cyclophosphamide-based conditioning including total body
irradiation with less frequent use of ATG or alemtuzumab,
and more frequent use of PBSCT and hematopoietic growth
factors after HCT (Table 1). In multivariate analysis
(Figure 1B), TACþMTX was associated with a lower risk of
mortality (HR, .42; 95% conﬁdence interval, .23 to .80;
P¼ .008). Other outcomes did not differ statistically between
the 2 regimens. No statistically signiﬁcant interactions were
observed between the main variable and the adjusted
covariates. Causes of death were similar between the 2 GVHD
prophylaxis regimens (overall P ¼ .91) (Table 2). Because
several studies showed inferior survival after PBSCT
compared with after BMT for SAA [21-24], stratiﬁed analysis
was also performed by graft type (Figure 2). Results for BMT
were similar to results of the nonstratiﬁed analysis. Results
for PBSCT showed no statistically signiﬁcant differences
for any outcome, but analytic power was limited in this
subgroup.
DISCUSSION
In the absence of a prospective, randomized comparison,
this large international cohort study provides valuable
information. Based on adjusted multivariate analyses, the
use of TACþMTX was unexpectedly associated with a lower
risk of mortality among URD recipients and with slightly
Table 1
Patient Characteristics
Characteristic HLA-identical Sibling (SIB) Unrelated Donor (URD)
CSPþMTX
(n ¼ 569)
TACþMTX
(n ¼ 62)
P* CSPþMTX
(n ¼ 198)
TACþMTX
(n ¼ 120)
P*
Patient age at transplantation, median (range), yr 19 (<1-66) 25 (2-70) <.001 18 (<1-61) 24 (2-68) <.001
Male patient 343 (60) 31 (50) .12 107 (54) 67 (56) .76
Patient race .003 .03
Caucasian 279 (49) 42 (68) 136 (69) 62 (52)
African-American 27 (5) 4 (6) 4 (2) 7 (6)
Asian/Paciﬁc Islander 131 (23) 2 (3) 36 (18) 27 (23)
Hispanic 88 (15) 11 (18) 11 (6) 14 (12)
Other 38 (7) 2 (3) 7 (4) 5 (4)
Missing 6 (1) 1 (2) 4 (2) 5 (4)
Donor age, median (range), yr 19 (<1-72) 23 (1-72) .03 32 (19-61) 29 (18-52) .02
Donor-recipient sex match .07 .82
Male-male 184 (32) 18 (29) 68 (34) 47 (39)
Male-female 129 (23) 12 (19) 66 (33) 37 (31)
Female-male 159 (28) 13 (21) 35 (18) 19 (16)
Female-female 97 (17) 19 (31) 23 (12) 16 (13)
Missing 0 0 6 (3) 1 (<1)
HLA matching NA .97
HLA-identical sibling 569 (100) 62 (100) 0 0
Unrelated well-matched 0 0 133 (67) 81 (68)
Unrelated partially-matched 0 0 45 (23) 27 (23)
Unrelated mismatched 0 0 15 (8) 8 (7)
Unrelated missing 0 0 5 (3) 4 (3)
Graft type .10 .008
BM 455 (80) 44 (71) 173 (87) 91 (76)
Mobilized PBSC 114 (20) 18 (29) 25 (13) 29 (24)
Pretransplantation therapy .03 .66
None 317 (56) 34 (55) 9 (5) 9 (8)
Any ATG 91 (16) 18 (29) 177 (89) 107 (89)
Any cyclosporine 71 (12) 3 (5) 7 (4) 1 (1)
Any others 87 (15) 6 (10) 4 (2) 3 (3)
Missing 7 (1) 2 (3) 2 (1) 1 (<1)
Time from SAA diagnosis to transplantation, median (range), mo 3 (<1-347) 3 (<1-500) .98 13 (2-316) 12 (2-298) .90
Year of transplantation <.001 .02
2001-2004 316 (56) 15 (24) 75 (38) 30 (25)
2005-2007 179 (31) 20 (32) 74 (37) 44 (37)
2008-2011 74 (13) 27 (44) 49 (25) 46 (38)
Conditioning regimen .03 .01
Fludarabine-included 127 (22) 11 (18) 89 (45) 37 (31)
Busulfan-included 67 (12) 1 (2) 4 (2) 1 (1)
CY  ATG  TBI 309 (54) 44 (71) 95 (48) 66 (55)
Others 66 (12) 6 (10) 10 (5) 16 (13)
Use of ATG/alemtuzumab in conditioning regimen or GVHD prophylaxis .002y <.001y
ATG rabbit 106 (19) 27 (44) 24 (12) 14 (12)
ATG horse 135 (24) 18 (29) 69 (35) 31 (26)
ATG unknown 128 (23) 7 (11) 82 (41) 26 (22)
Alemtuzumab 6 (1) 1 (2) 5 (3) 10 (8)
None 194 (34) 9 (15) 18 (9) 39 (33)
TBI dose in conditioning regimen NA <.001
None 560 (98) 58 (94) 68 (34) 15 (13)
800 cGy 7 (1) 4 (6) 121 (61) 95 (79)
>800 cGy 2 (<1) 0 8 (4) 10 (8)
Dose unknown 0 0 1 (1) 0
Use of growth factors after transplantationz 224 (39) 35 (56) .009 58 (29) 52 (43) .01
Median follow-up of survivors, (range), mo 62 (3-145) 54 (12-142) .41 61 (3-144) 61 (12-126) .16
NA indicates not applicable; BM, bone marrow; TBI, total body irradiation.
Data presented are n (%), unless otherwise indicated.
* Statistical tests used are chi-square test for independence for categorical variables and the Wilcoxon rank-sum test for continuous variables. Missing values
in categorical variables were excluded from statistical tests.
y P value reﬂects testing ATG or alemtuzumab versus none.
z G-CSF or GM-CSF given in time frame of 1 day before transplantation to 7 days after transplantation.
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expectations, the results did not show a lower risk of acute or
chronic GVHD with the use of TACþMTX, and we found no
statistically signiﬁcant differences in the risk of other out-
comes with the 2 prophylaxis regimens.
Although the number of SIB recipients treated with
TACþMTX was limited, the results showed no better out-
comes with the use of TACþMTX. Although the proportion ofdeaths caused by graft failure was higher with TACþMTX
than with CSPþMTX, the overall risk of death did not show
any statistically signiﬁcant differences. HR indicated trends
suggesting higher risks of acute and chronic GVHD with the
use of TACþMTX in SIB recipients. These results contrast
with results from previous studies of patients, mostly with
hematological malignancies, showing that the use of TACwas
associated with lower risks of acute GVHD [9,11,16], chronic
Figure 1. Comparison of outcomes with TACþMTX versus CSPþMTX. Hazard ratios with 95% conﬁdence intervals are shown for TACþMTX compared with CSPþMTX.
(A) Transplantation from an HLA-identical sibling (SIB). (B) Transplantation from an unrelated donor (URD). *All models were adjusted for graft type, year of
transplantation, and center effect. For grades II to IV GVHD in URD, results were adjusted for ABO matching, cytomegalovirus serology, HLA matching, pre-
transplantation therapy, and donor-recipient gender combination. For grades III to IV GVHD in SIB, results were adjusted for ABO matching. For grades III to IV GVHD
in URD, results were adjusted for donor age. For chronic GVHD in SIB, results were adjusted for patient age. For chronic GVHD in URD, results were adjusted for
patient age, HLA matching, time from SAA diagnosis to transplantation, pretransplantation therapy, and total body irradiation dose in conditioning regimen. For
mortality in SIB, results were adjusted for patient age, type of ATG or alemtuzumab in the conditioning regimen, or GVHD prophylaxis and cytomegalovirus serology.
For mortality in URD, results were adjusted for patient age, performance score at transplantation, and HLA matching. For ANC recovery in SIB, results were adjusted
for patient age and use of growth factors after transplantation. For ANC recovery in URD, results were adjusted for donor-recipient gender combination and use of
growth factors after transplantation. For platelet recovery in SIB, results were adjusted for ABO matching, patient age, type of ATG or alemtuzumab in the condi-
tioning regimen or GVHD prophylaxis, cytomegalovirus serology, time from SAA diagnosis to transplantation, and performance score at transplantation. For platelet
recovery in URD, results were adjusted for performance score at transplantation.
Table 2
Causes of Death
Cause of death, no. (%) HLA-identical
Sibling (SIB)
Unrelated
Donor (URD)
CSPþMTX TACþMTX CSPþMTX TACþMTX
Total no. 85 (100) 15 (100) 38 (100) 17 (100)
Infection 25 (29) 2 (13) 6 (16) 2 (12)
Organ failure 20 (24) 2 (13) 8 (21) 4 (24)
GVHD 16 (19) 0 (0) 10 (27) 4 (24)
Graft failure 8 (9) 7 (47) 4 (11) 2 (12)
Idiopathic pneumonia 5 (6) 1 (7) 5 (13) 1 (6)
Secondary malignancy 2 (2) 1 (7) 1 (3) 0 (0)
Others 9 (11) 2 (13) 4 (11) 4 (24)
Data presented are n (%), unless otherwise indicated.
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studies [16] but not others (Table 3) [9,11,12]. The relative
merits of TAC might differ according to the underlying dis-
ease because incidence rates of acute and chronic GVHD are
much lower after HCT among patients with SAA compared
with those with hematological malignancies.
Notably, the better survival with TACþMTX for URD
recipients was consistent with results from the previous
matched-pair study [15], but these results should be inter-
preted with caution because the lower mortality was not
explained by a lower risk of GVHD or by different causes of
death with the use of TACþMTX in either our study or the
previous matched-pair study. Differences in the distribution
Figure 2. Comparison of outcomes with TACþMTX versus CSPþMTX, stratiﬁed by donor and graft type. Hazard ratios with 95% conﬁdence intervals are shown for
TACþMTX compared with CSPþMTX. (A) Transplantation from an HLA-identical sibling. (B) Transplantation from an unrelated donor. Some results for PBSCT were
not available because of small numbers of events (grades III to IV acute GVHD and secondary graft failure in SIB; and grades III to IV acute GVHD in URD). *All models
were adjusted for year of transplantation and center effect. For grades II to IV GVHD in URD, results were adjusted for ABO matching, cytomegalovirus serology, HLA
matching, pretransplantation therapy, and donor-recipient gender combination. For grades III to IV GVHD in SIB, results were adjusted for ABO matching. For grades
III to IV GVHD in URD, results were adjusted for donor age. For chronic GVHD in SIB, results were adjusted for patient age. For chronic GVHD in URD, results were
adjusted for patient age, HLA matching, time from SAA diagnosis to transplantation, pretransplantation therapy, and total body irradiation dose in conditioning
regimen. For mortality in SIB, results were adjusted for patient age, type of ATG or alemtuzumab in the conditioning regimen or GVHD prophylaxis, and cyto-
megalovirus serology. For mortality in URD, results were adjusted for patient age, performance score at transplantation and HLA matching. For ANC recovery in SIB,
results were adjusted for patient age and use of growth factors after transplantation. For ANC recovery in URD, results were adjusted for donor-recipient gender
combination and use of growth factors after transplantation. For platelet recovery in SIB, results were adjusted for ABO matching, patient age, type of ATG or
alemtuzumab in the conditioning regimen or GVHD prophylaxis, cytomegalovirus serology, time from SAA diagnosis to transplantation, and performance score at
transplantation. For platelet recovery in URD, results were adjusted for performance score at transplantation.
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mortality associated with the use of TACþMTX. A lower risk
of mortality associated with TAC was reported in only 1
retrospective study of patients, mostly with hematological
malignancies [12], whereas other studies showed no statis-
tical differences in mortality between TAC and CSP among
URD recipients (Table 3) [10,11,13,16].
This study has several limitations. First, although the
center effect was adjusted in all models and was not statis-
tically associated with any outcomes, CIBMTR did not collectdata for blood concentrations of calcineurin inhibitors, the
doses and schedules of MTX administration, or the doses and
schedules of ATG or alemtuzumab at individual centers.
Practice variations could have affected the results of this
study. For example, omission of the day 11 methotrexate
dose can increase the risk of acute GVHD [25]. Second, the
choice between TAC and CSP might have been dictated by
center-speciﬁc prognostic factors not captured by CIBMTR,
which could have introduced some bias. Thus, the data do
not support any ﬁrm conclusions regarding the relative
Table 3
Results of Tacrolimus Compared with Cyclosporine in Previous Studies
Year 1998 2000 2001 2004 2009 2011 2012 2015
Author Ratanatharathorn [9] Nash [10] Hiraoka [11] Yanada [12] Yagasaki [15] Inamoto [13] Jagasia [16] Current
study
Design RCT RCT RCT Retro Retro Retro Retro Retro
No. of patients 329 180 136 2712 94 456 5561 949
Disease Any Any Any Any SAA Malignancy Malignancy SAA
Donor SIB URD SIB URD SIB URD URD Both SIB URD SIB URD
Graft type
BM 329 180 74 62 1507 777 94 0 806 1081 499 264
PBSC 0 0 0 0 428 0 0 456 2385 1289 132 54
II-IV GVHD Y Y Y Y ns Y ns ns Y Y ns ns
III-IV GVHD ns Y ns Y ns ns ns
Chronic GVHD Y ns Y Y Y ns ns ns ns ns
Overall mortality [ ns ns ns ns Y Y ns Y ns ns Y
ANC recovery ns ns ns ns ns [ ns
Recurrent malignancy ns ns [ ns ns ns ns
RCT indicates randomized controlled trial; Retro, retrospective analysis; ns, no statistical difference.
Y. Inamoto et al. / Biol Blood Marrow Transplant 21 (2015) 1776e1782 1781merits of TACþMTX versus CSPþMTX after HCT for acquired
SAA. Prospective studies would be needed to determine
whether the use of TACþMTX is associated with a lower risk
of mortality in URD recipients with acquired aplastic anemia.ACKNOWLEDGMENTS
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